GSK, ovarian cancer and Jemperli

GSK's cancer drug combo meets main goal in ovarian cancer trial
GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial,
Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal
Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter.
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.
GSK reports positive results from ovarian cancer drug trial
GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival.
GSK's Cancer Drugs Zejula, Jemperli Met Its Primary Key Goal in Late-Stage Study
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
ENDPOINTS NEWS1d
GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival
Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...
devdiscourse4h
Pharma Giants Face Challenges: A Snapshot of Recent Developments
The latest updates in the health sector involve significant trials and approvals. GSK's ovarian cancer drug trial met its ...
Pharmabiz13h
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
The Pharma Letter1d
Mixed results for GSK’s Zejula/Jemperli combo
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...
devdiscourse20h
Pharma Drama: A Rollercoaster Week in Health News
This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...
London South East1d
GSK reports mixed findings from ovarian cancer phase III study
(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial ...
GSK Reports Headline Results From FIRST-ENGOT-OV44 Phase III Trial - Quick Facts
GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...